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The response to the coronavirus disease 2019 (COVID-19) pandemic has been hampered by
lack of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral
therapy. Here we report the use of remdesivir in a patient with COVID-19 and the prototypic
genetic antibody deficiency X-linked agammaglobulinaemia (XLA). Despite evidence of
complement activation and a robust T cell response, the patient developed persistent SARS-
CoV-2 pneumonitis, without progressing to multi-organ involvement. This unusual clinical
course is consistent with a contribution of antibodies to both viral clearance and progression
to severe disease. In the absence of these confounders, we take an experimental medicine
approach to examine the in vivo utility of remdesivir. Over two independent courses of
treatment, we observe a temporally correlated clinical and virological response, leading to
clinical resolution and viral clearance, with no evidence of acquired drug resistance. We
therefore provide evidence for the antiviral efficacy of remdesivir in vivo, and its potential
benefit in selected patients.
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The prodrug nucleoside analog remdesivir is a broad-spectrumantagonist of viral RNA-dependent RNA polymerase (RdRp)enzymes, leading to inhibition of SARS-CoV-2 replication
in vitro1–3 and pre-clinical benefit in a macaque model of
COVID-19.4 Two recent RCTs have tested the efficacy of remdesivir
in patients. The first was underpowered, and failed to show clinical
benefit.5 Preliminary data from the second showed a statistically
significant reduction in illness duration, and a trend to reduced
mortality.6 No convincing evidence of virological efficacy was
reported in either study.
Although RCTs provide the gold-standard for evaluation of the
efficacy of new therapeutic interventions, comparing the average
responses of patients in heterogeneous treatment and control
groups may mask the potential benefits for individual patients.
Evaluation of therapeutics for COVID-19 is particularly compli-
cated by the highly variable clinical course. Furthermore, as well
as mediating clearance of SARS-CoV-2, the immune response
may also contribute to severe COVID-19 pathology, independent
of viral replication.
It is therefore unclear whether the limited response to remdesivir
observed in RCTs reflects inadequate in vivo antiviral activity, or
the need for concurrent immunomodulation. To minimize het-
erogeneity attributable to the immune response, we therefore take a
reductionist, experimental medicine approach to evaluate the effi-
cacy of remdesivir for treatment of COVID-19 in vivo, by studying
a rare patient in whom the contribution of humoral (antibody-
dependent) immunity to viral clearance and immunopathology is
controlled genetically by the primary immunodeficiency XLA.
Results
Uncomplicated persistent COVID-19 pneumonitis in a patient
with XLA. XLA is caused by mutations in the gene encoding
Bruton’s tyrosine kinase (BTK), leading to an absence of mature B
lymphocytes and immunoglobulins (antibodies). The subject of
this study is a 31-year-old man with XLA, whose past medical
history is summarized in the Methods. His illness began with
fever, cough, nausea, and vomiting. On day 19, a nasopharyngeal/
throat swab was positive for SARS-CoV-2 RNA, and he com-
menced treatment with hydroxychloroquine and azithromycin
(Supplementary Fig. 1). His symptoms persisted, and a repeat
nasopharyngeal/throat swab on day 28 remained positive for
SARS-CoV-2 RNA.
The patient was admitted to hospital on day 30 because of
worsening dyspnea, and supplemental oxygen was commenced
(Fig. 1a). Blood tests showed a rising CRP and mild lymphopae-
nia, elevated IL-6, IL-10, TNF-α, and IFN-γ, but normal D-Dimer
and troponin, with no evidence of significant coagulopathy, renal
or liver dysfunction (Fig. 1 and Tables 1–4). Blood and sputum
cultures for bacteria remained negative throughout the course of
the illness, procalcitonin was repeatedly normal, and two trials of
broad-spectrum intravenous antibiotics had no improved effect
(Supplementary Fig. 1). A sputum sample remained positive for
SARS-CoV-2 RNA, and a CT chest scan showed widespread
patchy ground-glass opacity in the lower lobes, consistent with
COVID-19 pneumonitis (Fig. 1b).
Immunocompetent adults with severe COVID-19 typically
exhibit a monophasic acute illness, with hospital admission and
progressive respiratory failure 7–10 days after symptom onset7,8.
In contrast, our patient exhibited a very unusual pattern of SARS-
CoV-2 infection, with persistent fever and pneumonitis for
>30 days, but without progression to acute respiratory distress
syndrome (ARDS) or multi-organ involvement. This relatively
stable baseline allowed the detailed assessment of clinical,
virological and immune responses during two independent
challenges with remdesivir.
Clinical response to remdesivir. On day 34, hydroxychloroquine
and azithromycin were discontinued, and the patient commenced
a 10 day course of remdesivir. His fever and dyspnea improved
within 36 hours of the first dose, nausea and vomiting ceased, and
rising oxygen saturation allowed discontinuation of supplemental
oxygen. This dramatic clinical response was accompanied by a
progressive decrease in CRP, a rise in total lymphocyte count, and
an improvement in ground-glass opacification on repeat CT chest
(Fig. 1a, b). The patient was therefore discharged on day 43.
Seven days after discharge, his fever, dyspnea, and nausea
returned. He was readmitted to hospital on day 54, and
supplemental oxygen was commenced. A further sputum sample
was positive for SARS-CoV-2 RNA, and a CT pulmonary
angiogram showed evidence of ongoing pneumonitis (Fig. 1a,
b). Consistent with a recrudescence of COVID-19, the patient’s
CRP increased, and his lymphocyte count fell. On day 61, he
therefore began treatment with a further 10 day course of
remdesivir. Once again, his symptoms rapidly improved, his fever
and requirement for supplemental oxygen resolved, and his CRP
and lymphocyte count normalized (Fig. 1a).
The patient therefore exhibited a marked clinical response,
tightly correlated with the administration of remdesivir, over two
independent challenges. Because of his underlying immunodefi-
ciency, protracted illness, and relapse after the first course of
remdesivir, he was further treated with two units of convalescent
plasma on days 69 and 70, to provide secondary prophylaxis
against SARS-CoV-2 infection (Fig. 1a). He was discharged 3 days
later, and has remained apyrexial and asymptomatic over a
further 28 days of follow-up.
Virological response to remdesivir. SARS-CoV-2 RNA was
identified on nasopharyngeal/throat swabs early in the patient’s
illness, but became undetectable on these samples from day 36
(Fig. 1a). Because of his underlying bronchiectasis, the patient
habitually expectorates small volumes of sputum. SARS-CoV-2
RNA was readily detectable in these samples until day 64, 4 days
into his second remdesivir course, allowing non-invasive mon-
itoring of his lower respiratory tract. Samples from blood, urine,
feces, and a rectal swab were all negative.
Strikingly, levels of SARS-CoV-2 RNA in sputum fell
progressively during the patient’s first course of remdesivir,
corresponding with his clinical response (Fig. 1a). Nonetheless,
SARS-CoV-2 RNA remained detectable at low levels. Upon
cessation of remdesivir treatment, levels of SARS-CoV-2 RNA
increased again in parallel with the recrudescence of symptoms.
The effect of the second course of remdesivir was even more rapid
and complete, with SARS-CoV-2 RNA becoming undetectable
after 4 days (Fig. 1a). The patient therefore exhibited a dramatic
virological response, tightly correlated with both the administra-
tion of remdesivir and resolution of his symptoms.
To confirm that the recurrent detection of SARS-CoV-2 RNA
reflected viral persistence, rather than reinfection, isolates were
sequenced regularly over the course of the patient’s illness (Fig. 1a
and Supplementary Fig. 2 and Table 5). All isolates belonged to
the B2.6 lineage, a very uncommon lineage globally with only 47
isolates in total from the UK, making reinfection extremely
unlikely. Compared with the Wuhan-Hu-1 reference sequence, 17
single-nucleotide polymorphisms (SNPs) were present in at least
one isolate (Supplementary Fig. 2). Among these, the only SNP in
the remdesivir target gene nsp12, encoding the RdRp, was a
synonymous variant (C14805T), present at equivalent abundance
across all isolates. Despite the combination of underlying
immunodeficiency, prolonged viral shedding and repetitive
treatment, there was therefore no evidence of acquired remdesivir
resistance.
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Contribution of antibodies to clearance of SARS-CoV-2. XLA
is the prototypic genetic disorder of the humoral immune system,
and the most obvious explanation for our patient’s failure to clear
his infection spontaneously is his lack of antibodies to SARS-CoV-
2. Patients with XLA are known to be at risk from persistent RNA
viral infections, particularly chronic enteroviral meningoence-
phalitis9. This risk is mitigated by immunoglobulin replacement
therapy, including antibodies to enteroviruses.10 Conversely,
available pooled immunoglobulin preparations antedate the
COVID-19 pandemic, and lack specific SARS-CoV-2 antibodies.
We therefore assessed the humoral immune response to SARS-
CoV-2 in our patient. As expected, despite maintenance of regular
immunoglobulin replacement, antibodies to SARS-CoV-2 spike
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prior to treatment with convalescent plasma (Fig. 2a, b), and no
neutralization activity was observed against lentiviral particles
pseudotyped with SARS-CoV-2 spike protein (Fig. 2c). Following
administration of convalescent plasma, antibody levels and
neutralisation activity rose commensurately (Fig. 2a–c).
CD8+ T-cell response to SARS-CoV-2. Together with CD8+
T cells, antibodies are known to contribute to the control of other
RNA viruses, including HIV11, Hepatitis C12, and LCMV infec-
tion of mice13,14. Some recent reports of patients with XLA and
COVID-1915–17 did not describe persistent clinical disease. This
suggests that, similar to the LCMV model, CD8+ T-cell immu-
nity can sometimes compensate for humoral deficiency in the
control SARS-CoV-2. We therefore assessed the antigen-specific
CD8+ T- response to SARS-CoV-2 in our patient.
Immunodominant CD8+ T-cell epitopes of SARS-CoV-218
and other coronaviruses19,20 are contained within the spike
protein. We first measured the quality of the CD8+ T-cell
response by flow cytometry for antigen-stimulated effector
protein expression21 (Fig. 3a). The frequency of spike-specific
CD8+ T cells within the circulation was comparable to age-
matched healthcare workers with acute COVID-19, trending
upwards over the course of infection. Increasing polyfunctional
effector capacity was evident from day 62 (Fig. 3b), particularly
the appearance of TNF-α and IFN-γ producing CD8+ T cells
(Supplementary Fig. 3).
We further assessed the coverage of the patient’s antigen-
specific response by measuring CD8+ T-cell proliferation to
peptide pools covering the S1, S2, M, N, ORF3, ORF6, ORF8, and
ORF7 SARS-CoV-2 proteins, following viral clearance. At days 77
and 83, the patient had striking responses to all viral peptides
Fig. 1 Clinical and virological assessment of the response to remdesivir. a Temperature, CRP, total lymphocyte count, and cycle-threshold (CT) value for
viral RNA amplification from patient samples, deducted from the CT value at the limit of detection (LoD) of the assay, plotted by day since symptom
onset, aligned with clinical interventions. Samples tested in the clinical laboratory at the Royal London Hospital are highlighted (*). Indicated viral isolates
a–g were analyzed by Nanopore sequencing (Supplementary Fig. 2 and Table 5). n= 1 biologically independent samples. b Computerized tomography (CT)
images at the level of the inferior pulmonary veins (top) and aortic arch (bottom) obtained at indicated time points. Prior to COVID-19 infection, there is
moderate bronchiectasis, mucoid impaction and small airway obstruction (black arrows) in the middle lobe and lingula, but the remainder of the lungs are
clear (Pre-COVID-19). Shortly before the first course of remdesivir, extensive ground-glass opacification and patchy consolidation with a lower lobe
predominance is seen, together with perivascular consolidation in the right upper lobe (Day 32). Nine days after initiation of remdesivir treatment there is
improvement in the lower zone ground-glass opacity and consolidation, but persistent consolidation in the right upper lobe and mild progression of the left
upper lobe subpleural consolidation (red arrows) (Day 42). 10 days after completion of the first course of remdesivir treatment, following relapse of
symptoms and fever, there is further improvement in the lower zone ground-glass opacification, but progressive subpleural consolidation, particularly in the
left upper lobe (blue arrows) (Day 53).
Table 1 Results from the clinical biochemistry laboratory, collated from readings at the indicated stages of the patient’s illness.









Serum sodium (mmol/litre) 135 (133–146) 139 (133–146) 134 (133–146)
Serum potassium (mmol/litre) 3.6 (3.5–5.3) 4.3 (3.5–5.3) 3.4 (3.5–5.3)
Serum urea (mmol/litre) 3.8 (2.5–7.8) 2.7 (2.5–7.8) 2.1 (2.5–7.8)
Serum creatinine (µmol/litre) 75 (62–115) 77 (62–115) 56 (62–115)
Albumin (g/litre) 28 (36–50)
Total bilirubin (µmol/litre) 9 (0–20) 5 (0–20)
Alkaline phosphatase (U/litre) 66 (30–130) 77 (30–130)
Alanine transaminase (U/litre) 26 (10–49) 13 (10–49)
Triglyceride (mmol/litre) 3.17 (0.3–1.8)
Abnormal results are shown in bold. Numbers in parentheses indicate reference values of the corresponding measurements.
Table 2 Results from the clinical hematology laboratory, collated from readings at the indicated stages of the patient’s illness.
Days after inpatient admission






D-Dimer (ng/ml) D-Dimer (ml/L FEU) 201 (0–230) 0.66 (0–0.5) 0.77 (0–0.5)
Fibrinogen (g/litre) 6.33 (1.46–3.33) 7.3 (1.46–3.33) 6.61 (1.46–3.33)
Ferritin (µg/L) 1063.5 (22–322) 410 (22–322) 546 (22–322)
Lactate dehydrogenase (U/litre) 620 (120–246)
NT pro BNP (pg/ml) 12
High sensitivity troponin (ng/litre) 5.8 (0–58.1)
APTT (sec) 36.1 (28.2–36.6) 28 (28.2–36.6)
PT (sec) 15.6 (10.8–13.3) 11.2 (10.8–13.3) 12 (10.8–13.3)
Abnormal results are shown in bold. Numbers in parentheses indicate reference values of the corresponding measurements. APTT activated partial thromboplastin time, PT prothrombin time.
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relative to age-matched COVID-19 infected HCWs (Fig. 3c, d),
likely reflecting the prolonged duration of antigen exposure.
Taken together, these data confirm the presence of a robust
CD8+ T-cell response to SARS-CoV-2. Although insufficient to
resolve the infection spontaneously, this likely contributed to the
clearance of virus during the second course of remdesivir.
Role of antibodies in immunopathogenesis of COVID-19. As
well as their role in the antiviral response, antibodies have the
potential to cause immune pathology22. In a retrospective study of
patients with SARS-CoV, the development of neutralizing anti-
bodies early in infection correlated with worse disease outcome23,
and high antibody titers are associated with severe disease in
COVID-1924. Our patient’s lack of SARS-CoV-2 antibodies may
therefore explain why, despite his persistent infection, he did not
progress to ARDS or multi-organ involvement.
Antigen–antibody complexes are able to activate the classical
complement pathway, with release of the anaphylatoxins C3a and
C5a and formation of the multi-subunit terminal complement
complex (TCC). C3-deficiency reduces lung pathology in a mouse
model of SARS-CoV25, complement activation is a feature of
Table 3 Results from the clinical immunology laboratory, collated from readings at the indicated stages of the patient’s illness.









IgG (g/litre) 9.6 (6.34–18.11) 13.8 (6.34–18.11) 16.5 (6.34–18.11)
IgA (g/litre) <0.3 (0.8–2.8) <0.05 (0.8–2.8) <0.05 (0.8–2.8)
IgM (g/litre) <0.2 (0.5–1.9) <0.05 (0.5–1.9) <0.05 (0.5–1.9)
Complement C3 (g/litre) 2.26 (0.75–1.65)
Complement C4 (g/litre) 0.66 (0.14–0.54)
Alternative pathway AP100 (%) >129 (66–129)
Classical pathway CH100 (U/ml) >911 (392–1019)
TNF Alpha (pg/ml) 15.65 (0–5)
IL-1 beta (pg/ml) 0.76 (0–3.1)
IL-10 (pg/ml) 2.91 (0–1)
IFN- gamma (pg/ml) 19.19 (< 10)
IL-6 (pg/ml) 31.8 (0–2)
CD3+ T cells
% 91 93
Total (×109 /litre) 1.21 (0.7–2.1) 1.61 (0.7–2.1)
CD4+ T cells
% 62 58
Total (×109 /litre) 0.82 (0.2–1.4) 1.01
CD8+ T cells
% 29 34
Total (×109 /litre) 0.39 (0.2–0.9) 0.58
CD19+ B cells
% 0 0
Total (×109 /litre) 0 (0.1–0.5) 0
CD56+ NK cells
% 9 6
Total (×109 /litre) 0.12 (0.09–0.6) 0.11
Abnormal results are shown in bold. Numbers in parentheses indicate reference values of the corresponding measurements.
Table 4 Results from the clinical microbiology laboratory, collated from readings at the indicated stages of the patient’s illness.









Procalcitonin (ng/ml) 0.15 (0–0.5) 0.06 (0–0.5)
HIV RNA Not detected
Adenovirus DNA Not detected
Human metapneumovirus RNA Not detected
Influenza A generic Not detected
Influenza B RNA Not detected
Parainfluenza virus RNA Not detected
RSV RNA Not detected
Picornavirus RNA Not detected
Numbers in parentheses indicate reference values of the corresponding measurements.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19761-2 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:6385 | https://doi.org/10.1038/s41467-020-19761-2 | www.nature.com/naturecommunications 5
COVID-1926, and deposition of TCC is observed in the
microvasculature of patients with severe disease27.
We therefore assessed the level of complement activation in
our patient. Despite the lack of disease progression, levels of C3a
C3c, C5a, and TCC were markedly elevated, comparable to levels
seen in COVID-19 patients admitted to the intensive care unit
(Fig. 4a–d). Although complement activation correlates with and
may be required for the development of ARDS and/or multi-
organ failure, complement activation alone is therefore insuffi-
cient for disease progression, and the classical pathway is not
required for complement activation in COVID-19.
Discussion
Taken together, our observations confirm that remdesivir is a
potent antiviral agent for treating SARS-CoV-2 infection in vivo. It
is striking that previous reports from immunocompetent patients
have generally not demonstrated the profound clinical and vir-
ological responses observed in this study. This is likely because,
among the hospitalized patients included in RCTs5,6 or compas-
sionate use programs28 to date, progression or resolution of disease
has been determined not by the level of SARS-CoV-2 replication,
but by the evolution of immune pathology. Although remdesivir
was given chronologically late in our patient’s disease, he had not
developed ARDS or multi-organ involvement. The utility of
remdesivir in immunocompetent patients may therefore be max-
imized by early treatment in the most at risk, or by combination
with targeted immunomodulatory therapies in the most sick.
Other reports of patients with XLA and COVID-19 have
described mild disease, of heterogenous duration.15–17,29,30
Similar to recent cases in which convalescent plasma was used for
treatment29,30, the persistent disease observed here strongly
suggests that antibodies contribute to the control of SARS-CoV-2,
at least in some patients. Alongside the failure of specific antibody
production, BTK is also expressed in other immune cells31,32, and
monocyte targeting by BTK inhibition can ameliorate COVID-
1933. Nonetheless, monocyte dysfunction in patients with XLA is
corrected by adequate replacement immunoglobulin34, and this
treatment effectively mitigates the immunodeficiency seen in
routine clinical practice.
The lack of disease progression observed in this patient suggests
that antibodies may also contribute to immune pathology in
COVID-19, and administration of convalescent plasma has the
potential to trigger an inflammatory response30. Aside from
Table 5 Viral sequence accession numbers that were compared to the reference GenBank accession MN908947.3.
Virus name COG-UK ID GISAID accession ENA accession ENA hyperlink
hCoV-19/England/CAMB-7FE20/
2020




















































































































































Fig. 2 Kinetic assessment of the antigen-specific humoral responses. Serological reactivity to SARS-CoV-2 spike a and nucleocapsid b antigens of patient
sera obtained at indicated time points, the first (CP 1) and second (CP 2) infusions of convalescent plasma (CP), sera from healthy controls (n= 8
biologically independent subjects) and patients (n= 5 biologically independent subjects) with PCR-confirmed COVID-19 (MFI, mean fluorescence
intensity; Mean and SEM). c Neutralisation activity against SARS-CoV-2 spike-pseudotyped lentiviral particles of patient sera obtained at indicated time
points, compared with the first (CP 1) and second (CP 2) infusions of convalescent plasma (CP). (n= 1 independent biological samples, n= 3 technical
replicates from each sample; mean and SD). Data from one independent experiment.
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Fig. 3 Kinetic assessment of the antigen-specific CD8+ T-cell responses. a % CD8+ T cells expressing activation makers after incubation ± a peptide
pool covering the SARS-CoV-2 S1 protein. Patient samples obtained at indicated time points are compared with HCWs with PCR-confirmed COVID-19 at
presentation (n= 5 biologically independent subjects). b Number of activation markers expressed by S1-responsive CD8+ T cells from a. Representative
flow cytometry dot plots c and % proliferating CD8+ T cells d after stimulation ± peptide pools covering the indicated SARS-CoV-2 proteins. Patient
samples are compared with HCWs (n= 2 biologically independent subjects) with PCR-confirmed COVID-19 at indicated time points. Data from one
independent experiment.
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activating complement, antibodies may interact with Fc receptors
on immune cells to drive macrophage activation and inflamma-
tory cytokine production35. Strategies that target these interactions
include plasmapheresis, or blockade of Fc receptors by saturating
doses of intravenous immunoglobulin. The potential for both
beneficial and deleterious effects of SARS-CoV-2 antibodies
revealed by our study suggests that these interventions, like the
administration of convalescent plasma, should be tailored to
individuals or subgroups of patients with distinct clinical
characteristics.
Methods
Oversight. The study was approved by the East of England—Cambridge South
national institutional ethics review board (17/EE/0025). The patient provided
written informed consent. Additional healthy controls, patients and healthcare
workers with COVID-19 provided written informed consent and were enrolled to
the NIHR BioResource Centre Cambridge (17/EE/0025) and the Oxford Gastro-
intestinal Illness Biobank (16/YH/0247).
Patient characteristics. The subject of this study is a 31-year old man, born in the
UK to parents of Pakistani origin, and diagnosed with XLA at the age of 12. He has
a family history of XLA affecting his brother, four maternal uncles and a male
maternal cousin. Following investigation for recurrent chest infections, he was
found to lack mature B cells and circulating immunoglobulins, and confirmed to
have inherited the familial c. 1430delT mutation in the gene encoding BTK.
Because of prior incomplete adherence to replacement immunoglobulin therapy,
he developed middle lobe bronchiectasis.
Remdesivir treatment. The first course of remdesivir was administered as part of
a Gilead SIMPLE study (NCT04292899), the second course was provided as part of
the Gilead Expanded Access Program (NCT04323761). In each case, the patient
received an initial dose of 200 mg IV, followed by niine daily doses of 100 mg IV
(10 days total).
Convalescent plasma. Convalescent plasma was collected from individuals with
previous, laboratory-confirmed SARS-CoV-2 infection at least 28 days after reso-
lution of symptoms using established infrastructure and standard UK donor
selection guidelines, as previously described36. Signed consent was obtained from
each donor at the time of donation using NHS Blood and Transplant-approved
consent forms, in accordance with Blood Safety and Quality Regulations enforced
by the Medicines & Healthcare products Regulatory Agency.
In brief, a total of at least 540 ml of plasma (containing < 1 × 106 leukocytes
per component) was collected via plasmapheresis from each donor, divided into
two units, rapidly frozen and stored at −25 °C. Donor blood samples were tested
for SARS-CoV-2 RNA (Public Health England) and antibodies (EUROIMMUN
(IgG) assay, PerkinElmer, London, UK). A signal to cutoff (S/CO) ratio of 9.1 in
the EUROIMMUN assay was previously shown to identify donations with a
neutralizing antibody titre of ≥1:100 in a SARS-CoV-2 (isolate England/2020)
microneutralisation assay with a specificity of 100%.36 Both donations used in
this study were collected in May 2020 and confirmed to be negative for
SARS-CoV-2 RNA. EUROIMMUN S/CO ratios were 37.171 (first unit, 290 ml,
administered on day 69) and 7.271 (second unit, 283 ml, administered on day
70), respectively. For the second unit (lower S/CO ratio), the neutralizing
antibody titre was confirmed to be ≥1:100 using the SARS-CoV-2
microneutralisation assay.36 Plasma was defrosted using a 37°C waterbath, and
transfused within 4 hours of defrosting.
Patient sampling. Upper respiratory tract samples (nasopharyngeal/throat swabs)
were collected in viral transport medium according to Public Health England
(PHE) guidelines. Lower respiratory samples (sputum) were collected in universal
containers and extracted following mucolysis with Mucolyse PL.701 sputum
liquefying agent (Pro-Lab Diagnostics). To minimize RNA degradation, the time
between sample collection and processing did not exceed 2 hr.
Peripheral blood mononuclear cells (PBMCs) were isolated using Leucosep
tubes (Greiner Bio-One) with Histopaque-1077 (Sigma) by centrifugation at 800 ×
g for 15 mins at room temperature. PBMCs at the interface were collected and
rinsed twice with autoMACS running buffer (Miltenyi Biotech). All samples were
processed within 4 h of venepuncture. Samples were then resuspended in freezing
medium (FBS 90% supplemented with dimethyl sulfoxide (DMSO) 10%), frozen
overnight at −80 °C in a Mr Frosty cell freezing containger (Nalgene) then
transferred to liquid nitrogen for long term storage.
SARS-CoV-2 molecular testing. Sample testing was carried out using an in-house
real time uniplex RT-PCR diagnostic assay for the detection of SARS-CoV-2 in the
PHE Clinical Microbiology and Public Health Laboratory at Addenbrooke’s
Hospital, Cambridge. This assay targets a 222 base-pair region of the SARS-CoV-2
nsp12 gene (encoding RdRp), and has been validated for clinical use.
In brief, nucleic acid extraction was undertaken using the NUCLISENS
easyMAG platform (Biomerieux, Marcy L-Etoile), in accordance with the
manufacturer’s instructions. Nucleic acids were extracted from 500 μL sample, with
a dilution of MS2 bacteriophage (4600pfu per extraction) added pre-extraction to
act as an internal extraction and inhibition control. Molecular grade water was used
as a negative control. Positive control material, BetaCoV/England/02/2020, was
obtained from PHE Colindale (essentially, purified viral RNA diluted to give a
cycle-threshold (CT) value of 26–28).
The RdRp gene was detected using primers ATGGGTTGGGATTATCC
TAAATGTGA and AGCAGTTGTGGCATCTCCTGATGAG with a FAM-labeled
MGB RdRp Probe ATGCTTAGAATTATGGCCTCAC. The internal extraction
control was detected using the MS2 forward primer TGGCACTACCCCTCTCC
GTATTCACG, the MS2 reverse primer GTACGGGCGACCCCACGATGAC and
a ROX-BHQ2 labeled MS2 probe CACATCGATAGATCAAGGTGCCTACAAGC.
Amplification reactions and detection of PCR products were performed using the
RotorgeneTM PCR instrument. A typical reaction contained 400 nM of forward
and reverse primers for the RdRp gene and 200 nM of the MS2 internal control
forward and reverse primer pair, along with 120 nM of the RdRp and MS2 probes.
The cycle conditions were as follows: 25 °C 2mins, 50 °C 15 mins, 95 °C 2 mins
followed by 45 cycles of 95 °C and 60 °C. Samples that generated a CT value ≤36,
defined as 0.01 fluorescence units as per the RotorgeneTM manufacturer’s
instructions, were considered positive (roughly equivalent to eight genome copies,
the lower limit of detection for the assay). Where indicated, additional samples































































































































a b c d
Fig. 4 Assessment of complement activation. Concentrations of complement cleavage products C3a a, C3c b, and C5a c, and circulating terminal
complement complex (TCC) d at indicated time points, compared with healthy controls or patients with PCR-confirmed COVID-19 (healthcare workers,
HCW or patients with severe disease admitted to the intensive therapy unit, ITU; mean and SEM are shown). For a and b HCW, n= 5 biologically
independent subjects and ITU n= 5 biologically independent subjects. For c Healthy controls, n= 12 biologically independent subjects and ITU n= 51
biologically independent subjects. d Healthy controls, n= 67 biologically independent subjects and ITU n= 50 biologically independent subjects. Data from
one independent experiment.
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Viral sequencing and bioinformatics. Samples were analyzed by Nanopore
sequencing as part of the COG-UK sequencing project, following the ARTICnet-
work V3 protocol (https://doi.org/10.17504/protocols.io.bbmuik6w), and assem-
bled using the ARTICnetwork assembly pipeline (https://artic.network/ncov-2019/
ncov2019-bioinformatics-sop.html). The accession numbers of the sequences
included in this study are available in Table 5. Median genome depth of coverage
was 1346×. Consensus FASTA sequences were analyzed after QC filtering, de-
duplication and matching with metadata. Variants were initially assessed using the
ARTICnetwork assembly pipeline VCF output files, with a SNP being called when
>50.1% frequency at a single base. These were then independently confirmed using
iVar analysis (https://andersen-lab.github.io/ivar/html), set to a quality threshold of
Q20 and a minimum frequency of 10%, with a SNP being called when >50.1% of
the reads at a particular position differed from the reference sequence, Wuhan-Hu-
1 (GenBank Accession MN908947.3). The location of each SNP was examined to
identify mutations in the nsp12 gene, encoding RdRp (the target of remdesivir
treatment). For the kinetic assessment, proportions of each variant as a fraction of
all reads at their corresponding locations (minimum depth 20×) were plotted as a
proportional stacked area chart using ggplot2 and RStudio.
Intracellular cytokine staining. Cryopreserved PBMCs were rapidly thawed,
washed in R10 media (RMPI-1640+10% FBS+1% Pen/Strep), and 106 cells added
to wells of a 96-well U-bottom plate. Cells were stimulated with 2g/ml overlapping
S1 or M peptide pools, or left unstimulated, for 2 h at 37 °C, 5% CO2. Anti-CD107a-
BV785 (1:100 dilution, clone H4A3), anti-CD28 (clone CD28.2, 1 µg/ml) and anti-
CD49d (clone R1-2, 1 µg/ml) to all wells at the time of peptide addition. After 2 h,
brefeldin A (5 µg/ml) and monensin (2 µM) were added, and cells were incubated at
37 °C, 5% CO2 for an additional 16 hr. After stimulation, cells were washed two
times with fluorescence-activated cell sorting (FACS) buffer (PBS+1mM EDTA+
0.05% BSA). Surface staining was performed at 4 °C for 30mins. Cells were then
washed two times in FACS buffer, and fixed and permeabilized at 4 °C for 30mins
using BD Cytofix/Cytoperm solution. Cells were then washed twice with 1× BD
Perm/Wash buffer, and stained for intracellular markers at 4 °C for 30 mins. Two
further washes with 1× BD Perm/Wash buffer were performed and cells were stored
in FACS buffer at 4 °C. Samples were acquired on a custom Cytek Aurora spectral
analyzer (four laser; UV, violet, blue, and red) using SpectroFlo v2.2. Data were
analyzed using FlowJo v. 10.6.2 and Prism v. 8.3.0.
T-cell proliferation assay. Freshly isolated PBMCs were labeled using CellTrace
Violet (Invitrogen) and stimulated with peptide pools spanning the entire S, M, N,
and ORFs 3, 6, 7, and 8 SARS-CoV-2 proteins at 1 µg/ml of each overlapping
peptide. Stimulation was done in Roswell Park Memorial Institute (RPMI) media
(Sigma) supplemented with 10% AB serum (Sigma), 1% Pen/strep and 1% L glu-
tamine for 7 days at 37 °C. 0.1% DMSO, representative of DMSO content in
peptide stimulated wells, was used as negative control and 2 µg/ml of PHA (Sigma)
served as positive control. On day 4, 100 µl of media was exchanged with 100 µl of
fresh media. On day 7, cells were washed using FACS wash buffer (Biolegend) and
stained with L/D Near Infra red (Invitrogen), CD3 FITC (Biolegend) at 1:50
dilution, CD4 AF700 (BD Bioscience) at 1: 100 dilution and CD8 PECY7 (Biole-
gend) at 1:200 dilution. Samples were subsequently fixed and acquired on a BD LSR
II. Data were analyzed using flowjo v10.6.2.
Serological assessment. Serological reactivity to SARS-CoV-2 spike and nucleo-
capsid proteins: recombinant SARS-CoV-2 nucleocapsid and spike proteins were
covalently coupled to distinctive carboxylated bead sets (Luminex; Netherlands) to
form a multiplex assay. For protein coupling, beads were first activated with 1-
ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (Thermo Fisher Sci-
entific) in the presence of N-hydroxysuccinimide (Thermo Fisher Scientific),
according to the manufacturer’s instructions, to form amine-reactive intermediates.
The activated bead sets were incubated with the corresponding proteins at a
concentration of 50 μg/ml in the reaction mixture for 3 h at room temperature on a
rotator. Beads were washed and stored in a blocking buffer (10 mM PBS, 1% BSA,
0.05% NaN3).
Coupled bead sets were incubated with patient or control sera at a dilution
of 1/100 for 1 h in 96-well filter plates (MultiScreenHTS; Millipore) at room
temperature in the dark on a horizontal shaker. Fluids were aspirated with a
vacuum manifold and beads were washed three times with 10 mM PBS/0.05%
Tween-20. Beads were incubated for 30 mins with a PE-labeled anti–human IgG-Fc
antibody (Leinco/Biotrend), washed as described above, and resuspended in 100 μl
PBS/Tween-20. They were then analyzed on a Luminex analyzer (Luminex/R&D
Systems) using Exponent Software V31. Specific binding was reported as mean
fluorescence intensities. Stored sera collected in the diagnostic immunology
laboratory prior to November 2019 were used as healthy controls. Sera collected
from patients with PCR-confirmed COVID-19 were used as positive controls.
Neutralisation activity. Cell lines: HEK293T (Lehner laboratory stocks) and
HEK293T + ACE2 cells were cultured in Iscove’s Modified Dulbecco’s Media
(Sigma) supplemented with 1% GlutaMAX™, 10% FCS, 100units/ml penicillin and
100 µg/ml streptomycin (all Thermo Fisher), at 37 °C in 5% CO2. HEK293T cells
constitutively expressing angiotensin-converting enzyme 2 (ACE2) (HEK293T+
ACE2 cells) were generated by transduction of wildtype HEK293T cells with a
pHRSIN-ACE2-hygroR lentivirus and selected 48 h post transduction using 100 µg/
mL hygromycin B (Sigma). All cells were confirmed to be mycoplasma negative
(MycoAlert, Lonza).
Plasmids: plasmid pCG1-SARS-CoV-2 Δ19 expressing humanized SARS-CoV-2
Δ19 spike was created by amplification of truncated spike from pCG1-SARS-2-S
(a kind gift from M. Hoffmann, Infection Biology Unit, Leibniz Institute for
Primate Research, Gottingen, Germany) using Phusion polymerase (NEB) and
primer pair CoV2optFor (ttgtatcggatccaccatgttcgtgtttctggtgctgctg) and
CoV2optD19rev (atcccgatctagatcagcagcagctgccacagctaca). The amplified product,
lacking the C-terminal 19 amino acids, was digested and re-cloned into the pCG1
vector using BamHI-XbaI sites. pHRSIN-ACE2-hygroR was produced by cloning
into KpnI-XhoI-digested pHRSIN-pSFFV MCS(+) pGK-Hygro using NEBuilder
HiFi DNA assembly (NEB) of the ACE2 gene amplified from HepG2 mRNA, using
Phusion polymerase (NEB) and primer pair ACE2-cDNA_Fwd
(cgcccgggggggatccactaggtaccatgtcaagctcttcctggctcc) and ACE2_cDNA_Rev
(ctagagtcgcggccgctctactcgagctaaaaggaggtctgaacatcatcagtgttttg), following reverse
transcription using Superscript III (Thermo Fisher) and oligo (dT)15 (Promega).
pHRSIN-firefly luc-PuroR was produced by ligation of the BamHI–NotI-digested
firefly luciferase cDNA into BamHI-NotI-digested pHRSIN-pSFFV-EmGFP
pGK puro.
Virus production: pseudotyped lentiviral stocks were generated through the co-
transfection of HEK293T cells with a lentiviral expression vector plus the
packaging plasmid pCMVΔR8.91 and either pMD.G (VSV-G) or pCG1-SARS-
CoV-2 Δ19 spike plasmid, using TransIT-293 transfection reagent (Mirus)
according to the manufacturer’s recommendations. Viral supernatants were
harvested 48 h post transfection and cell debris was removed with a 0.45-um filter
prior to use or freezing.
Neutralisation assay: pseudotyed pHRSIN-firefly luc-PuroR lentivirus
supernatants were pre-incubated with diluted serum or plasma samples at 37 °C for
60 mins, before addition of 1.25 × 104 HEK293T cells to each well. Transduction
efficiencies were quantified 48 h post transduction by measuring firefly luciferase
activity in cell lysates using Bright-Glo™ luciferase assay system (Promega) and read
in a CLARIOstar luminometer. Data were plotted using GraphPad Prism 8 (non-
linear regression, (Inhibitor) vs. response–Variable slope, four parameters) and
virus neutralizing antibody titre was obtained by determining the dilution factor
which gave a 50% reduction in firefly luciferase levels, compared with the no serum
control wells.
Complement assays. The complement components C3a, C3c, and C5a were
measured in plasma samples from patients with COVID-19 using solid-phase
enzyme-linked immunosorbent assay (ELISA, Hycult Biotech) according to the
manufacturer’s instructions. TCC was measured using an in-house ELISA with the
anti-TCC neo-epitope antibody, ae11, used at 5 µg/ml as capture.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All relevant data are available from the authors. Viral sequence data are available from
COVID-19 Genomics UK and the GSAID. The accession numbers are detailed in Table 5
and are accessible from https://www.cogconsortium.uk/data/. Source data are provided
with this paper.
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